RTK aids life sciences companies in achieving their strategic
goals by leveraging our extensive industry knowledge in technology and healthcare.
Unravel Biosciences is a therapeutics company that spun out from the Wyss Institute for Biologically Inspired Engineering at Harvard University in early 2021 to seamlessly bridge target discovery with clinical efficacy to advance drugs. Unravel leverages its proprietary BioNAV™ platform combining drug discovery, patient stratification and preclinical screening to find treatments for complex diseases impacting the whole body. By combining dynamic transcriptome data with proprietary maps of human health, Unravel identifies similar patient groups based on network signatures and matches them with compounds that reverse disease. Evaluation in the automated SquishyWare™ in vivo screen identifies effective hits that improve clinically relevant metrics and are used to uncover hidden drug targets.
ROMEG’s goal is to provide plant originated solutions for every day ailments. We are patient and physician focused. Our mission is to address unmet or underserved medical needs with products that are targeted, patient-friendly and nature-originated. We are focused on building a product pipeline by redesigning currently FDA approved treatments to offer benefits to patients and physicians.
RTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.
We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.